Vemurafenib-induced pancreatitis in a patient with recurrent hairy cell leukaemia.
Su Yun ChungJanice Gloria ShenCristina M GhiuzeliPublished in: BMJ case reports (2020)
Recent studies have shown that BRAF inhibitors, such as vemurafenib, are effective in inducing long periods of remission in relapsed hairy cell leukaemia. Acute pancreatitis is one of the rare complications that is reported with vemurafenib use. As severe pancreatitis can be life threatening, physicians should be vigilant of this side effect and promptly treat patients that develop clinical signs and symptoms while receiving vemurafenib. We present an interesting case of vemurafenib-induced pancreatitis that not only resolved but also did not recur after reintroduction of the drug at a reduced dose.
Keyphrases
- drug induced
- single cell
- high glucose
- diabetic rats
- cell therapy
- end stage renal disease
- ejection fraction
- newly diagnosed
- primary care
- acute lymphoblastic leukemia
- acute myeloid leukemia
- chronic kidney disease
- prognostic factors
- case report
- oxidative stress
- diffuse large b cell lymphoma
- early onset
- rheumatoid arthritis
- endothelial cells
- systemic lupus erythematosus
- bone marrow
- disease activity
- patient reported outcomes
- adverse drug
- metastatic colorectal cancer
- ulcerative colitis